ADAM12 and colorectal adenocarcinoma: In the “colorectal adenocarcinoma TCGA Firehose Legacy” dataset, patients with a high expression of ADAM12 (z-score > 0.2) had a poorer overall survival ((OS); median OS = 63 months) compared to patients with a low ADAM12 expression (z-score < 0.2; median OS = undefined; Figure 2A; p = 0.006; HR = 1.84).